Healthcare Business Update: Questcor’s Deerfield Interest, Isis Craters On FDA Briefing

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

ArQule (NASDAQ:ARQL) reaches an agreement with the FDA to design a Phase-3 trial of its drug tivantinib in patients suffering from hepatocellular carcinoma, a type of liver cancer. Shares moved up on the day accordingly.

Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) moved up impressively Tuesday after James Flynn of Deerfield Management reported a 5.82 percent passive interest in the firm late Monday.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

StemCells (NASDAQ:STEM) shares popped following the intro of four new human neural stem cell kits under its SC Proven brand for use in neuroscience research. Each unit will contain high purity, multi-potent neural stem cells obtained from a different area of the human central nervous system and will supply researchers with a platform through which to perform a broad range of assays and tests.

Shares of Isis Pharmaceuticals (NASDAQ:ISIS) tumbled sharply subsequent to an FDA panel posting briefing documents for its Hypercholesterolemia treatment Kynamro. The briefing indicates an “unexpected” level of uncertainty because the drug, which will be before a panel of non-FDA experts on Thursday responsible with recommending approval, has been shown to cause an increase in cancers in rats. Further, it has also been attributed to fat buildup in the liver which can cause long-term damage.

Don’t Miss: Here’s What the FDA Has to Say About Isis Pharmaceuticals.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business